Discovery of a novel small molecule as CD47/SIRPα and PD-1/PD-L1 dual inhibitor for cancer immunotherapy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Discovery of a novel small molecule as CD47/SIRPα and PD-1/PD-L1 dual inhibitor for cancer immunotherapy ; volume:22 ; number:1 ; day:11 ; month:3 ; year:2024 ; pages:1-16 ; date:12.2024
Cell communication and signaling ; 22, Heft 1 (11.3.2024), 1-16, 12.2024
- Urheber
-
Jin, Shengzhe
Wang, Hongfei
Li, Yang
Yang, Jingwen
Li, Beibei
Shi, Peishang
Zhang, Xiangrui
Zhou, Xiaowen
Zhou, Xiuman
Niu, Xiaoshuang
Wu, Menghan
Wu, Yahong
Zhai, Wenjie
Qi, Yuanming
Gao, Yanfeng
Zhao, Wenshan
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12964-024-01555-4
- URN
-
urn:nbn:de:101:1-2405140752446.412714072733
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:56 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Jin, Shengzhe
- Wang, Hongfei
- Li, Yang
- Yang, Jingwen
- Li, Beibei
- Shi, Peishang
- Zhang, Xiangrui
- Zhou, Xiaowen
- Zhou, Xiuman
- Niu, Xiaoshuang
- Wu, Menghan
- Wu, Yahong
- Zhai, Wenjie
- Qi, Yuanming
- Gao, Yanfeng
- Zhao, Wenshan
- SpringerLink (Online service)
Ähnliche Objekte (12)
Dual blockage of both PD-L1 and CD47 enhances immunotherapy against circulating tumor cells
Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
PD-L1 degradation pathway and immunotherapy for cancer
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Clinical applications of PD-L1 bioassays for cancer immunotherapy
RNAi-Mediated PD-L1 Inhibition for Pancreatic Cancer Immunotherapy
PD-L1 blockade immunotherapy rewires cancer-induced emergency myelopoiesis
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
PD-L1 siRNA hitched polyethyleneimine-elastase constituting nanovesicle induces tumor immunogenicity and PD-L1 silencing for synergistic antitumor immunotherapy
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Dual blockage of both PD-L1 and CD47 enhances immunotherapy against circulating tumor cells
Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
PD-L1 degradation pathway and immunotherapy for cancer
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Clinical applications of PD-L1 bioassays for cancer immunotherapy
RNAi-Mediated PD-L1 Inhibition for Pancreatic Cancer Immunotherapy
PD-L1 blockade immunotherapy rewires cancer-induced emergency myelopoiesis
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
PD-L1 siRNA hitched polyethyleneimine-elastase constituting nanovesicle induces tumor immunogenicity and PD-L1 silencing for synergistic antitumor immunotherapy
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Dual blockage of both PD-L1 and CD47 enhances immunotherapy against circulating tumor cells
Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
PD-L1 degradation pathway and immunotherapy for cancer
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Clinical applications of PD-L1 bioassays for cancer immunotherapy
RNAi-Mediated PD-L1 Inhibition for Pancreatic Cancer Immunotherapy
PD-L1 blockade immunotherapy rewires cancer-induced emergency myelopoiesis
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
PD-L1 siRNA hitched polyethyleneimine-elastase constituting nanovesicle induces tumor immunogenicity and PD-L1 silencing for synergistic antitumor immunotherapy
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer